

### 3.05 1<sup>st</sup> Irish National Pulmonary Hypertension Audit - 2021-2022

Margaret Higgins<sup>1</sup>, Nizrull Nasir<sup>1</sup>, Foad Bukhari<sup>1</sup>, Luke Forde<sup>1</sup>, Salima Meghani<sup>1</sup>, Denise Lennon<sup>1</sup>, Caitriona Minnock<sup>1</sup>, Ciara McCormack<sup>1</sup>, Sarah Cullivan<sup>1</sup> Brian McCullagh<sup>1</sup>, Sean Gaine<sup>1</sup>, Syed Rehan Quadery<sup>1</sup>

1. National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland

**Background:** Pulmonary hypertension (PH) is a rare, debilitating and life shortening condition which is defined by a mean pulmonary arterial pressure of < 20 mmHg at rest on right heart catheterization. The National Pulmonary Hypertension Unit (NPHU) in Dublin is the quaternary referral centre for patients with PH in Ireland. The 2022 ESC/ERS PH guidelines recommend annual audit of the PH service. Until recently there was no annual audit in Ireland.

We aimed to create an active registry of patients with PH and measure the quality of care provided to the patients referred to our centre using the standards in the UK National Audit of PH.

**Methods:** This retrospective study identified patients who presented to the NPHU between April 2021 to March 2022.

**Results:** 265 patients were identified. Baseline characteristics are highlighted in **table 1** and results in **table 2**.

**Conclusion:** This study demonstrates the importance of a PH registry in Ireland to identify any potential shortcomings in our care. We sense that the Covid-19 pandemic has had a significant impact on our service. We plan to continue to reaudit our service and maintain an active registry to enhance the care of PH patients in Ireland.

**Table 1.**

<b>Patient Characteristics</b>	
<b>Patients, n</b>	265
<b>Gender, n (%): female</b>	180 (67)
<b>Age (years): mean (±SD)</b>	60 (17)
<b>Attendance type, n (%)</b>	
<b>New</b>	60 (22.6)
<b>Follow up</b>	205 (77.4)

**Table 2.**

<b>Results</b>
----------------

<b>Diagnosis within 6 months, n(%)</b>	
No	8 (11)
Yes	65 (89)
<b>Seen or discharged within 30 days, n(%)</b>	
No	22 (30.6)
Yes	50 (69.4)
<b>Pre-treatment RHC, n(%)</b>	
No	3 (5.7)
Yes	50 (94.3)
<b>6MWD and FC, n(%)</b>	
No	107 (45.7)
Yes	127 (54.3)
<b>Vasoreactivity Testing , n(%)</b>	
No	28 (87.5)
Yes	4 (12.5)
<b>Drug within 12 weeks, n(%)</b>	
No	12 (24.0)
Yes	38( 76.0)
<b>If on PH drug, diagnosis recorded, n(%)</b>	
No	15 (7.4)
Yes	188 (92.6)
<b>1<sup>st</sup> line used (PDE5i), n(%)</b>	
No	102 (87.2)
Yes	15 (12.8)
<b>QoL score documented, n(%)</b>	
No	251 (99.6)
Yes	1 (.04)
<b>Annual Consultation, n(%)</b>	
No	16 (7.6)
Yes	195 (92.4)
<b>PEA wait-time &lt;4months, n(%)</b>	

No	20 (95.2)
Yes	1 (4.8)
<b>BPA wait-time &lt;18 weeks, n(%)</b>	
No	9 (100)

**Table 2.** Abbreviations: RHC: right heart catheterisation; 6MWD: 6-minute walk distance; FC: functional class; PDE5i: phosphodiesterase type 5 inhibitor; QoL: quality of life; PEA: pulmonary endarterectomy; BPA: balloon pulmonary angioplasty

### Keywords

Pulmonary Hypertension; Audit; Quality and Safety; Clinical Governance

### Disclosures

No relevant disclosures to declare